For patients aged 1 month to 50 years with suspected bacterial meningitis, which regimen is recommended?

For patients aged 1 month to 50 years with suspected bacterial meningitis, which regimen is recommended?

• A. Cefotaxime plus Vancomycin.
• B. Vancomycin alone.
• C. Aminoglycoside alone.
• D. Ceftriaxone plus Vancomycin.

Answer: (D)

Empiric treatment for suspected bacterial meningitis in patients from 1 month to 50 years aims to cover Neisseria meningitidis, Streptococcus pneumoniae (including penicillin-resistant strains), and Haemophilus influenzae. A third‑generation cephalosporin with excellent CNS penetration paired with vancomycin provides the broad coverage needed before culture results are available. Ceftriaxone covers the common meningitis pathogens well and penetrates the CSF effectively when meningitis is present, while vancomycin adds protection against penicillin‑resistant pneumococcus. This combination is the standard first‑line regimen for this age group because it reduces the risk of treatment failure due to resistant pneumococcus and ensures coverage of N. meningitidis and Hib. Vancomycin alone lacks coverage of many meningitis pathogens (like Neisseria meningitidis and other Gram‑negatives), and an aminoglycoside alone has poor CSF penetration and limited CNS activity, so those options are not appropriate as single agents. Cefotaxime plus vancomycin is similar in rationale to the chosen regimen, but ceftriaxone is generally preferred for this age group due to pharmacokinetics and dosing convenience, making Ceftriaxone plus Vancomycin the best-supported choice here.

Empiric treatment for suspected bacterial meningitis in patients from 1 month to 50 years aims to cover Neisseria meningitidis, Streptococcus pneumoniae (including penicillin-resistant strains), and Haemophilus influenzae. A third‑generation cephalosporin with excellent CNS penetration paired with vancomycin provides the broad coverage needed before culture results are available. Ceftriaxone covers the common meningitis pathogens well and penetrates the CSF effectively when meningitis is present, while vancomycin adds protection against penicillin‑resistant pneumococcus. This combination is the standard first‑line regimen for this age group because it reduces the risk of treatment failure due to resistant pneumococcus and ensures coverage of N. meningitidis and Hib.

Vancomycin alone lacks coverage of many meningitis pathogens (like Neisseria meningitidis and other Gram‑negatives), and an aminoglycoside alone has poor CSF penetration and limited CNS activity, so those options are not appropriate as single agents. Cefotaxime plus vancomycin is similar in rationale to the chosen regimen, but ceftriaxone is generally preferred for this age group due to pharmacokinetics and dosing convenience, making Ceftriaxone plus Vancomycin the best-supported choice here.